Semler Scientific's Bitcoin holding strategy could lead to 150% stock price rise

US health tech company Semler Scientific steps up strategy to hold Bitcoin as an asset, sending shares up 150%
According to The Block on the 8th (local time), investment bank Benchmark has started a stock analysis on Semler and has a buy opinion.
The company also set a target price of $101, which means the stock has an upside potential of about 139% from the closing price of the stock on July 2 ($42.28).
"Semler is a real
"Through execution, transparency and investor communication, we can close the gap with other bitcoin holdings in terms of mNAV (net asset value multiple)," Semra said.
The company launched a formal Bitcoin treasury strategy in May 2024 and currently holds a total of 4,636 BTC, worth roughly $430 million.
This follows Strategy's strategy to put Bitcoin at the center of the company's asset portfolio, "The
The move marks the second US public company to adopt the Bitcoin Standard. Semler recently appointed Joe Barnett as head of Bitcoin strategy.
The company also released a blueprint to hold up to 105,000 BTC over a three-year period, specifically: △10,000 BTC by the end of 2025
The plan is to hold 42,000 BTC by the end of 2026 and 105,000 BTC by the end of 2027. BenchMARK plans to hold 42,000 BTC by the end of 2026 and 105,000 BTC by the end of 2027.
BenchMARK values SMLR shares on the assumption that the price of cryptocurrency will rise to $225,000. SMLR has an mNAV multiple of 1.25, according to BenchMARK, which has also adopted the same strategy.
Metaplanet (4.29), European Blockchain Group,
This is significantly lower than the 6.45) calculated based on the number of diluted shares relative to the amount of Bitcoin held.
The BTC yield is about 294%, which is a good level compared to competitors. The reasons for this low valuation include the sluggish growth of the company's core healthcare business, as well as the investigation by the US Department of Justice (DOJ).
The decision also reflects regulatory risks, such as uncertainty over Medicare volume and the like. However, Benchmark said, "Once the Department of Justice issue is resolved, a SaaS-based solution for the early diagnosis of heart failure will be developed.
"If the subsidiary CardioVanta gets off the ground, investor attention may refocus on Bitcoin strategies and the growth potential of the technology."